# US 2026/0218172 A1 · Rna guided compositions for preventing and treating hepatitis b virus infections

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0218172 A1
- Document ID: US20260218172A1
- Status: Published application
- Kind: A1
- Application number: 19/404,723
- Filed: 2025-12-01
- Published: 2026-07-30
- Earliest claimed: 2016-06-07
- Assignees: Temple University of the Commonwealth System of Higher Education
- Applicants: Temple University - of the Commonwealth System of Higher Education
- Inventors: Kamel Khalili; Hassen Wollebo
- Web page: https://patentgrep.com/patent/US20260218172A1

## CPC

- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 38/46: Hydrolases (3)
- A61K 38/465: {acting on ester bonds (3.1), e.g. lipases, ribonucleases}
- A61P 31/20: for DNA viruses
- C07K 14/00: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C12N 9/222: {Clustered regularly interspaced short palindromic repeats [CRISPR]-associated [CAS] enzymes}
- C12N 15/1131: {against viruses}
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2800/80: Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Compositions that specifically cleave target sequences in Hepadnaviridae, for example Hepatitis B virus (HBV) include nucleic acids encoding a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR) associated endonuclease and a guide RNA sequence complementary to a target sequence in HBV. These compositions are administered to a subject for eradicating an infection, latent or otherwise, or at risk for contracting HBV infection.

## Claims

### Claim 1

A composition for eradicating a hepadnavirus in vitro or in vivo, the composition comprising: an isolated nucleic acid sequence encoding a Clustered Regularly interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease and at least one guide RNA (gRNA), the gRNA being complementary to a target nucleic acid sequence in a hepadnavirus genome.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the hepadnavirus is hepatitis B virus (HBV).

### Claim 3 (depends on 1)

The composition of claim 1, wherein the target nucleic acid sequence comprises one or more nucleic acid sequences in coding and non-coding nucleic acid sequences of the hepadnavirus genome.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the target nucleic acid sequence comprises one or more sequences within a sequence encoding structural proteins, nonstructural proteins or combinations thereof.

### Claim 5 (depends on 4)

The composition of claim 4, wherein the nucleic sequences encoding structural proteins or non-structural proteins comprise C, X, P, and S nucleic acid sequences or combinations thereof.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the gRNA sequence has at least a 75% sequence identity to target nucleic acid sequences comprising C, X, P, and S nucleic acid sequences or combinations thereof.

### Claim 7 (depends on 1)

The composition of claim 1, wherein the gRNA sequences have at least a 75% sequence identity to sequences comprising: SEQ ID NO: 1-18, or combinations thereof.

### Claim 8 (depends on 7)

The composition of claim 7, wherein the gRNA sequences comprise: SEQ ID NO: 1-18, or combinations thereof.

### Claim 9 (depends on 1)

The composition of claim 1, further comprising two or more gRNAs.

### Claim 10 (depends on 9)

The composition of claim 9, wherein the two or more gRNAs are complementary to overlapping target sequences, distinct target sequences or combinations thereof.

### Claim 11

(canceled)

### Claim 12

(canceled)

### Claim 13

(canceled)

### Claim 14

A composition for eradicating a hepadnavirus in vitro or in vivo, the composition comprising: an isolated nucleic acid sequence encoding a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease and two or more guide RNAs (gRNAs), the gRNAs being complementary to a target nucleic acid sequence in a hepadnavirus genome.

### Claim 15 (depends on 14)

The composition of claim 14, wherein the two or more gRNAs are complementary to overlapping target sequences, distinct target sequences or combinations thereof.

### Claim 16

(canceled)

### Claim 17

(canceled)

### Claim 18

An isolated nucleic acid sequence comprising at least a 50% sequence identity to one or more sequences comprising SEQ ID NOS: 1 to 30.

### Claim 19 (depends on 18)

The isolated nucleic acid sequence of claim 18, wherein the sequences comprise any one or more of SEQ ID NOS: 1 to 30.
